Eisai Provides Preliminary efficacy In In EORTC study phase Dacogen Versus Supportive Care in patients with myelodysplastic syndromesEORTC – 06011: This Phase III open-label, randomized, multicenter, controlled study of overall survival of patients evaluated receiving Dacogen plus BSC versus BSC only. The study included 233 elderly patients. Greater than or equal to 60 years old, with predominantly high-risk or Intermediate-2 type MDS.

Please visit for the full Prescribing Information.About Eisai Corporation of North AmericaEisai Corporation of North America is a wholly owned subsidiary of Eisai Co. Is a research-based human health care company that discovers, develops and markets the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology / critical care.Dr. Werner been Career Development Award Career Development Award. Department of Veterans Affairs supported Please refer the item for more info including other author, author Review and affiliations, financial disclosures, financing and support.

Other articles from category "hepatology":

Random articles